Recent Finacing
Recent Raise
nChroma Bio develops epigenetic editors paired with programmable non-viral in vivo delivery; its liver-targeted CRMA-1001 modulates gene expression without DNA cutting and showed durable HBV/HDV reductions in preclinical models.
